Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa; Hideki Tani; Yuki Anraku; Shunsuke Kita; Emiko Igarashi; Yumiko Saga; Noriko Inasaki; Hitoshi Kawasuji; Hiroshi Yamada; so-Ichiro Sasaki; Mayu Somekawa; Jiei Sasaki; Yoshihiro Hayakawa; Yoshihiro Yamamoto; Yoshitomo Morinaga; Nobuyuki Kurosawa; Masaharu Isobe; Hideo Fukuhara; Katsumi Maenaka; Takao Hashiguchi; Hiroyuki Kishi; Isao Kitajima; Shigeru Saito; Hideki Niimi

doi:10.1080/19420862.2022.2072455

mAbs (Dec 2022)

Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

Tatsuhiko Ozawa,
Hideki Tani,
Yuki Anraku,
Shunsuke Kita,
Emiko Igarashi,
Yumiko Saga,
Noriko Inasaki,
Hitoshi Kawasuji,
Hiroshi Yamada,
so-Ichiro Sasaki,
Mayu Somekawa,
Jiei Sasaki,
Yoshihiro Hayakawa,
Yoshihiro Yamamoto,
Yoshitomo Morinaga,
Nobuyuki Kurosawa,
Masaharu Isobe,
Hideo Fukuhara,
Katsumi Maenaka,
Takao Hashiguchi,
Hiroyuki Kishi,
Isao Kitajima,
Shigeru Saito,
Hideki Niimi

Affiliations

Tatsuhiko Ozawa: Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Hideki Tani: Department of Virology, Toyama Institute of Health, Toyama, Japan
Yuki Anraku: Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Shunsuke Kita: Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Emiko Igarashi: Department of Virology, Toyama Institute of Health, Toyama, Japan
Yumiko Saga: Department of Virology, Toyama Institute of Health, Toyama, Japan
Noriko Inasaki: Department of Virology, Toyama Institute of Health, Toyama, Japan
Hitoshi Kawasuji: Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Hiroshi Yamada: Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
so-Ichiro Sasaki: Section of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan
Mayu Somekawa: Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Jiei Sasaki: Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
Yoshihiro Hayakawa: Section of Host Defences, Department of Bioscience, Institute of Natural Medicine, University of Toyama, Japan
Yoshihiro Yamamoto: Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Yoshitomo Morinaga: Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Nobuyuki Kurosawa: Department of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan
Masaharu Isobe: Department of Life Sciences and Bioengineering, Laboratory of Molecular and Cellular Biology, Faculty of Engineering, Academic Assembly, University of Toyama, Toyama, Japan
Hideo Fukuhara: Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Katsumi Maenaka: Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Takao Hashiguchi: Laboratory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan
Hiroyuki Kishi: Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan
Isao Kitajima: Administrative office, University of Toyama, Toyama, Japan
Shigeru Saito: Administrative office, University of Toyama, Toyama, Japan
Hideki Niimi: Department of Clinical Laboratory and Molecular Pathology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan

DOI: https://doi.org/10.1080/19420862.2022.2072455
Journal volume & issue: Vol. 14, no. 1

Abstract

Read online

Many potent neutralizing SARS-CoV-2 antibodies have been developed and used for therapies. However, the effectiveness of many antibodies has been reduced against recently emerging SARS-CoV-2 variants, especially the Omicron variant. We identified a highly potent SARS-CoV-2 neutralizing antibody, UT28K, in COVID-19 convalescent individuals who recovered from a severe condition. UT28K showed efficacy in neutralizing SARS-CoV-2 in an in vitro assay and in vivo prophylactic treatment, and the reactivity to the Omicron strain was reduced. The structural analyses revealed that antibody UT28K Fab and SARS-CoV-2 RBD protein interactions were mainly chain-dominated antigen-antibody interactions. In addition, a mutation analysis suggested that the emergence of a UT28K neutralization-resistant SARS-CoV-2 variant was unlikely, as this variant would likely lose its competitive advantage over circulating SARS-CoV-2. Our data suggest that UT28K offers potent protection against SARS-CoV-2, including newly emerging variants.

Published in mAbs

ISSN: 1942-0862 (Print); 1942-0870 (Online)
Publisher: Taylor & Francis Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Therapeutics. Pharmacology; Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: https://www.tandfonline.com/journals/kmab

About the journal

Abstract

Keywords